MA
GYRE icon

MUFG Americas’s Gyre Therapeutics GYRE Stock Holding History

MUFG Americas’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5
Closed -$11K – 1187
2015
Q2 		$11K Hold
5
– – ﹤0.01% 854
2015
Q1 		$11K Buy
5
+1
+25% +$2.07K ﹤0.01% 903
2014
Q4 		$8K Buy
+4
New +$7.71K ﹤0.01% 996

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

MUFG Americas's GYRE Position: Q3 2015 in Review

MUFG Americas sold out of Gyre Therapeutics (GYRE) in Q3 2015, closing a stake of 5 shares — an estimated $11K sold.

MUFG Americas first reported a position in GYRE in Q4 2014 and held it in 3 quarters. The position peaked at $11K in Q2 2015. 39 funds tracked by Wall St. Rank hold GYRE as of Q3 2015.

  • MUFG Americas reported no remaining Gyre Therapeutics position as of Q3 2015 after selling out during the quarter.
  • MUFG Americas sold 5 Gyre Therapeutics shares in Q3 2015, an estimated $11K.
  • MUFG Americas first reported a position in Gyre Therapeutics in Q4 2014 and held it in 3 quarters.
  • MUFG Americas's Gyre Therapeutics position peaked at $11K in Q2 2015.
  • 39 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2015.

Based on MUFG Americas's 13F filing for Q3 2015, filed 10 Nov 2015.